BiotechTube

Montelukast plus prednisolone + Prednisolone

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Asthma, Bronchial

Conditions

Asthma, Bronchial

Trial Timeline

Sep 1, 2005 → Feb 1, 2008

NCT ID
NCT00213252

About Montelukast plus prednisolone + Prednisolone

Montelukast plus prednisolone + Prednisolone is a phase 2 stage product being developed by Merck for Asthma, Bronchial. The current trial status is completed. This product is registered under clinical trial identifier NCT00213252. Target conditions include Asthma, Bronchial.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00213252Phase 2Completed

Competing Products

20 competing products in Asthma, Bronchial

See all competitors
ProductCompanyStageHype Score
RoflumilastAstraZenecaPhase 3
77
DuleraMerckApproved
85
BriquilimabJasper TherapeuticsPhase 1
25
YHD001 dose level 1 + YHD001 dose level 2 + Singulair + PlaceboYuhanPhase 2
52
RoflumilastAstraZenecaPhase 3
77
OmalizumabDaiichi SankyoPhase 3
77
OmalizumabDaiichi SankyoPhase 3
77
Tacrolimus Inhalation AerosolAstellas PharmaPhase 2
52
Regadenoson + PlaceboAstellas PharmaApproved
85
TacrolimusAstellas PharmaPhase 2
52
tacrolimusAstellas PharmaPhase 2
52
Zero-dose + 90 mcg of PROAIR® HFA + 180 mcg of 90 mcg of PROAIR® HFA + 90 mcg of albuterol sulfate inhalation aerosolSun PharmaceuticalPhase 3
77
rabeprazoleEisaiPhase 3
77
KHK4563 + KHK4563 + KHK4563 + PlaceboKyowa KirinPhase 2
52
Placebo + BrodalumabKyowa KirinPhase 2
52
ONO-6950 + ONO-6950 + Montelukast + PlaceboOno PharmaceuticalPhase 2
52
ONO-6950 + Placebo + MontelukastOno PharmaceuticalPhase 2
52
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + PlaceboCiplaPhase 3
77
Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg + Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol + PlaceboCiplaPhase 3
77
90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + PlaceboCiplaPhase 3
77

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85